[ad_1]
Emerging data shows that healthcare providers in the UAE are foraying into precision medicine, a new approach that is transforming healthcare from a ‘one size fits all’ approach to a targeted and personalized approach.
In the field of genetics, the rise of precision medicine in the Middle East and North Africa region, which has been reported to be dominated by defective genes mainly due to inbreeding, could benefit greatly from accurate reference genomes of key alleles.
Dr Maryam Matar, Founder and Chairman, UAE Genetic, said: “Personalized medicine is undoubtedly making the healthcare ecosystem better, driven by digitization and a rapidly growing knowledge base that is redefining how we view deadly diseases Origins and Development.” Society for Diseases at the Precision Medicine Exhibition & Summit in Dubai this past May.
Global data and insights company Netscribes expects the Middle East and Africa precision medicine market to grow at a CAGR of $2.51 billion by 2023 at a CAGR of 9.96%.
David Stradling, Events Director summit says The application of digital technologies, including artificial intelligence, big data, and machine learning, is propelling precision medicine as the vanguard of a new era of healthcare that can be tailored to individual needs, improving outcomes and the patient experience.
Personalized solutions are gaining popularity in genomics and targeted cancer therapy, regenerative medicine and now include a wide range of diagnostics and treatments for rare and common diseases.
“Healthcare providers in the GCC have entered the PM field, which is expected to grow at an annual rate of 11% through 2026 and be worth $142 billion globally,” said Mohammed bin Rashid University of Medicine and Health Sciences (MBRU) in Dubai. ) and King Faisal specialist hospitals and research centers in Saudi Arabia have established biomedical and genomics research centers and other institutions are expected to follow,” he said.
The UAE is one of the few countries in the MENA region that has adopted a modern and innovative approach to healthcare to address such issues. The Abu Dhabi Department of Health (DoH) recently launched the region’s first personalized precision medicine program for oncology.
On November 8, Illumina, a company specializing in DNA sequencing and array-based technologies, launched its newest, state-of-the-art Solutions Center in Dubai. “As the healthcare system’s demand for genomic testing continues to grow, Illumina Solutions Centere will help deliver accurate and actionable reports to clinicians and their patients,” said Susan Tousi, Illumina Chief Commercial Officer.
Asma Ali Zain is an independent journalist and regular contributor to Omnia Health.
<< Back to Lab
[ad_2]
Source link